False-Negative Neuroendocrine Tumor Identified With 68Ga-DOTATOC PET/CT: A Case of Well-Differentiated Somatostatinoma

Aurélie Moreau; Charlotte Chaouat; Thomas Walter; Aurélien Dupré; David Kryza

doi:10.1097/RLU.0000000000005241

False-Negative Neuroendocrine Tumor Identified With 68Ga-DOTATOC PET/CT: A Case of Well-Differentiated Somatostatinoma

Clin Nucl Med. 2024 May 1. doi: 10.1097/RLU.0000000000005241. Online ahead of print.

Authors

Aurélie Moreau¹, Charlotte Chaouat¹, Thomas Walter², Aurélien Dupré¹, David Kryza

Affiliations

¹ From the Centre Léon Bérard.
² Hospices Civils de Lyon, Lyon.

PMID: 38689443
DOI: 10.1097/RLU.0000000000005241

Abstract

We report the case of a 25-year-old man who was undergoing follow-up for neurofibromatosis type 1. The man underwent 68Ga-DOTATOC PET/CT for a suspected well-differentiated duodenal neuroendocrine tumor. This examination did not reveal any significant uptake, whereas complementary 18F-FDG PET/CT showed moderate 18F-FDG uptake in the primary tumor as well as the adenopathy. Histology, a well-differentiated duodenal neuroendocrine tumor was confirmed, consistent with the diagnosis of somatostatinoma. Although rare, this well-differentiated neuroendocrine tumor should be kept in mind as a possible source of false-negative somatostatin receptor PET/CT findings.